Valeria Santini
0000-0002-5439-2172
Publication & Citation Trends
Publications
0 total
Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes
Cited by 0
Semantic Scholar
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat
Cited by 0
Semantic Scholar
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study.
Cited by 0
Semantic Scholar
Increased duration of time without transfusion reliance with imetelstat versus placebo in the phase 3 IMerge trial
Cited by 0
Semantic Scholar
Impact of Mutational Landscape and Burden on RBC Transfusion Response in Patients With Lower‐Risk Myelodysplastic Syndromes (LR‐MDS) in the COMMANDS Study
Cited by 0
Semantic Scholar
Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS
Cited by 1
Semantic Scholar
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes
Cited by 5
Semantic Scholar
POSTER: MDS-249 Outcomes With Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs)
Cited by 0
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(508)
Myeloproliferative Neoplasms: Diagnosis and Treatment
(225)
Hemoglobinopathies and Related Disorders
(132)
Chronic Myeloid Leukemia Treatments
(87)
Chronic Lymphocytic Leukemia Research
(79)
Affiliations
Università Cattolica del Sacro Cuore
Liechtenstein Institute
Boston Children's Hospital
Cleveland Clinic
Sunnybrook Health Science Centre